Last week was the annual Biotechnology Industry Organization (BIO) annual convention in Philadelphia where medical innovations were abundant and showed remarkable promise. More than 17,000 delegates representing government, academia, and non-profit research institutes joined more than 4,000 companies in the City of Brotherly Love. The delegates share a common commitment to improve the quality and longevity of life through development of innovative new technologies, many of which are being commercialized at a pace not seen before. From vaccines to cell therapies and gene therapies, new products are promising substantial improvements to human health.
Posted By Scott Deeter on 6/10/19 2:12 PM
Posted By Marcus Curl on 5/29/19 1:00 PM
Reconstitute Optiferrin to create a 200 mg/ml stock solution. Sterile-filter stock solution. Supplement into hematopoietic stem-cell culture media. For best results, titrate within the recommended range of 50 to 150 mg/L concentration to determine the optimal Optiferrin concentration for the specific application.
Recently I had the opportunity to attend the Treg Summit in Boston to listen to the ground-breaking clinical and preclinical research in re-balancing the immune system in the context of autoimmunity and organ transplant via the use of polyclonal or antigen-induced T regulatory cells. Overall, this cell therapy holds immense promise as evidenced by both preclinical models and early clinical evaluations.
Posted By Marcus Curl on 5/14/19 1:20 PM
Worldwide, researchers and industry leaders are improving health outcomes for patients by utilizing the multi-functional efficacy of regulatory t cells to develop novel therapies and disease treatments. Regulatory T cells, commonly referred to as ‘T-regs’, play a critical role in maintaining order in the human immune system by regulating and suppressing excessive inflammation. Given the therapeutic potential of T-regs for patients with autoimmune diseases, cancer, and organ transplants, both researchers and industry leaders are developing novel therapies that utilize the multi-functional efficacy of T-reg cells in disease treatments to improve health outcomes for patients.
Cellastim S Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells
Posted By Jeanne McAdara Ph.D. on 5/9/19 11:00 AM
The number and breadth of applications for induced human embryonic and pluripotent stem cells (hi-ESCs and hi-PSCs) in both research and clinical settings continue to co-evolve with our understanding of how to harness them as biological tools.